Integrated genomic analyses of ovarian carcinoma
DR Bell, A. Berchuck, Michael J. Birrer, M. Imielinski, D. W. Cramer, F. Dao, D. A. Levine, N. Olvera, R. Dhir, Philip John DiSaia, Hani Gabra, P. Glenn, Karen Smith‐McCune, A K Godwin, J. Gross, Beth Y. Karlan, Sandra Oršulić, David D. Huntsman, Steven E. Kalloger, M. Iacocca, Brenda Rabeno, G. B. Mills, J.N. Weinstein, C. Morrison, D. Mutch, K. Park, N. Petrelli, Janet Sue Rader, Branimir Ivan Sikic, Anil K. Sood, David D.L. Bowtell, R. Penny, T. Shelton, M. Hatfield, S. Morris, P. Yena, P. Rhodes, M. Sherman, Joseph Paulauskis, S. Millis, JR Testa, K. Chang, CJ Creighton, H. H. Dinh, J. A. Drummond, G. Fowler, P. Gunaratne, A. C. Hawes, C. Kovar, L. R. Lewis, M. B. Morgan, Irene Newsham, J. Santibanez, J. G. Reid, L. R. Trevino, Y.-Q. Wu, M. Wang, Donna Marie Muzny, D. A. Wheeler, Richard A. Gibbs, Gad A. Getz, Michael S. Lawrence, Kristian Cibulskis, Doug Voet, Kristin Ardlie, Eric S. Lander, Matthew M. Meyerson, Roel G.W. Verhaak, Scott L. Carter, Craig H. Mermel, Gordon Saksena, H. Nguyen, Robert C. Onofrio, D. Hubbard, Sumeet Gupta, Andrew Crenshaw, Alex H. Ramos, Andrey Sivachenko, R. Jing, Richard W. Park, Michael S. Noble, Carrie L. Sougnez, Wendy Winckler, J. Wilkinson, J. Baldwin, R. Nichol, S. Fisher, T. Bloom, Stacey Gabriel, L. Ding, Robert S. Fulton, D.C. Koboldt, Michael D. McLellan
Nature · 2011 · 8,091 citationsOpen access
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Bell, D., Berchuck, A., Birrer, M. J., Imielinski, M., Chien, J., Cramer, D. W., Dao, F., Levine, D. A., Olvera, N., Dhir, R., DiSaia, P. J., Gabra, H., Glenn, P., Smith‐McCune, K., Godwin, A. K., Gross, J., Karlan, B. Y., Oršulić, S., Hartmann, L., … McLellan, M. D. (2011). Integrated genomic analyses of ovarian carcinoma. Nature, 474(7353), 609–615. https://doi.org/10.1038/nature10166
In text: (Bell et al., 2011)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
A catalogue of molecular aberrations that cause ovarian cancer is critical for developing and deploying therapies that will improve patients’ lives. The Cancer Genome Atlas project has analysed messenger RNA expression, microRNA expression, promoter methylation and DNA copy number in 489 high-grade serous ovarian adenocarcinomas and the DNA sequences of exons from coding genes in 316 of these tumours. Here we report that high-grade serous ovarian cancer is characterized by TP53 mutations in almost all tumours (96%); low prevalence but statistically recurrent somatic mutations in nine further genes including NF1, BRCA1, BRCA2, RB1 and CDK12; 113 significant focal DNA copy number aberrations; and promoter methylation events involving 168 genes. Analyses delineated four ovarian cancer transcriptional subtypes, three microRNA subtypes, four promoter methylation subtypes and a transcriptional signature associated with survival duration, and shed new light on the impact that tumours with BRCA1/2 (BRCA1 or BRCA2) and CCNE1 aberrations have on survival. Pathway analyses suggested that homologous recombination is defective in about half of the tumours analysed, and that NOTCH and FOXM1 signalling are involved in serous ovarian cancer pathophysiology. The Cancer Genome Atlas (TCGA) project reports here its analysis of messenger RNA and microRNA expression, promoter methylation, DNA copy number and exome sequences in 489 high-grade serous ovarian adenocarcinomas. The analyses help establish new tumour subtypes. Among other insights is the finding that while the gene encoding p53 tumour suppressor is mutated in almost all tumours, nine other loci including NF1, BRCA1, BRCA2, RB1 and CDK12 carry recurrent albeit low-prevalence mutations. Homologous recombination is defective in about half of the tumours studied, and Notch and FOXM1 signalling are involved in the pathophysiology.
Related papers
Metadata from OpenAlex (CC0). Citations are generated from the published record.